Back to Search
Start Over
Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report.
- Source :
- Cell Transplantation; Jan-Dec2022, Vol. 31, p1-6, 6p
- Publication Year :
- 2022
-
Abstract
- Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years. Among them, the CAR-NK (natural killer) therapy has shown better efficacy, and less toxicity, than chimeric antigen receptor T-cell (CAR-T) therapy. In our phase II clinical trials, administering chimeric costimulatory converting receptor (CCCR)-NK92 cells on advanced non-small cell lung cancer patients proved efficacious in cell and animal experiments. However, we observed occurrence of cytokine release syndrome (CRS), a rare and unexpected side effect, never reported before during CAR-NK therapy. Here, we provide a detailed report of the patient's case, emphasize on the need to pay attention to CRS in NK cell therapy, and suggest improvements that will minimize potential toxicity. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09636897
- Volume :
- 31
- Database :
- Complementary Index
- Journal :
- Cell Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 161033827
- Full Text :
- https://doi.org/10.1177/09636897221094244